A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
About
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for patients with rare diseases and conditions with high unmet medical need. The company's lead product candidate, pegtaralgene (CHTR-001), is in development for the treatment of nephropathic cystinosis. Travere also has a pipeline of other rare disease programs.
Tags
Total Employees
125
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Travere Therapeutics do?
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for patients with rare diseases and conditions with high unmet medical need. The company's lead product candidate, pegtaralgene (CHTR-001), is in development for the treatment of nephropathic cystinosis. Travere also has a pipeline of other rare disease programs.
How much funding has Travere Therapeutics raised?
Travere Therapeutics has raised a total of $63M in funding. The most recent round on record is Convertible Note.
Where is Travere Therapeutics headquartered?
Travere Therapeutics is headquartered in San Diego, California, USA.
When was Travere Therapeutics founded?
Travere Therapeutics was founded in 2015.
What industry does Travere Therapeutics operate in?
Travere Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Rare Diseases, Drug Discovery, Clinical Trials.
How many employees does Travere Therapeutics have?
Travere Therapeutics has approximately 125 people on record.
Similar Startups